February 20, 2024 05:23 AM ESTUpdated 06:38 AM
R&D

NodThera touts po­ten­tial weight loss ef­fect of NL­RP3 in­hibitors

Katherine Lewin

News Reporter

NodThera is mov­ing its NL­RP3 in­hibitors in­to the clin­ic af­ter pre­clin­i­cal da­ta showed it re­versed obe­si­ty and in­flam­ma­tion in mice in a study that com­pared …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

A service from the Financial Times